LEIDOS BIOMEDICAL RESEARCH INC: $342M Department of Health and Human Services Contract
Summary
Leidos Holdings ($LDOS) was awarded a $342M task order from the NIH for NCI operations, representing ~2.2% of annual revenue. The contract reinforces Leidos' position in health IT and government services, with moderate positive impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Leidos wins $342M NIH task order for NCI operations, adding ~2.2% to annual revenue.
- 2.Contract is a delivery order under existing IDIQ, indicating stable recurring business.
- 3.No direct legislative catalyst, but NIH funding is consistent with healthcare appropriations.
Market Implications
The contract is positive for LDOS, reinforcing its health segment revenue. However, given the company's $15.3B revenue base, the impact is moderate. Other health IT firms like $BAH or $ORCL may see indirect benefits if they are subcontractors, but no direct linkage is confirmed. The contract does not signal a sector-wide shift, but it underscores steady demand for health IT services from the NIH.
Full Analysis
The Department of Health and Human Services, through the National Institutes of Health, awarded a $342M delivery order to Leidos Biomedical Research Inc. for the NCI Operational Task Order covering FY26-FY27. This is a single-year contract (August 2025 to August 2026) providing operational support to the National Cancer Institute. Leidos Holdings, Inc. ($LDOS) is the direct parent company, as confirmed by SEC filings. With FY2025 revenue of $15.3B, this contract adds about 2.24% to top-line revenue. However, Leidos' net margin is only 1.3%, so the net income contribution is roughly $4.4M, which is less than 2.2% of net income. The contract is a renewal or continuation of existing work, not a new market entry.
Leidos' health segment is a key differentiator, and this contract provides stable revenue visibility. The company has a strong track record with NIH and other federal health agencies. The contract is a delivery order, meaning it was issued under a previously awarded indefinite-delivery/indefinite-quantity (IDIQ) contract, reducing competitive risk. No related legislation appears to directly authorize this specific task order, but NIH funding is part of annual appropriations.
Supply chain beneficiaries are likely smaller IT and consulting firms that subcontract to Leidos. Common subcontractors in this space include Cerner (now part of Oracle Health, $ORCL) and Booz Allen Hamilton ($BAH), though neither is a direct subcontractor here. Pure-play health IT firms like Health Catalyst ($HCAT) or Evolent Health ($EVH) could benefit indirectly if they provide specialized services, but the connection is weak.
Historically, Leidos has seen steady revenue growth from NIH contracts, and the stock tends to react positively to large task order awards, though the magnitude of price movement is usually modest (1-3%) given the company's size and diversification. The contract does not shift competitive dynamics, but it reinforces Leidos' position as a top-tier health IT contractor.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct award of a delivery order under an existing contract for operational support to the National Cancer Institute.
Who must act
National Institutes of Health (NIH) as the awarding agency; Leidos Biomedical Research Inc. as the recipient and prime contractor.
What happens
$342 million added to Leidos' backlog, representing approximately 2.24% of its FY2025 annual revenue of $15.3 billion.
Stock impact
This task order strengthens Leidos' health and life sciences segment, which is a core growth area. The low net margin (1.3%) means the net income impact is modest, but the contract reinforces long-term relationships with NIH and provides stable revenue.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
LEIDOS BIOMEDICAL RESEARCH INC: $485M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $338M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $372M Department of Health and Human Services Contract
LEIDOS, INC.: $18.8M Department of Homeland Security Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restriction on Entry of Certain Nonimmigrant Workers
This proclamation extends for an additional 12 months the existing restriction on entry of H-1B nonimmigrant workers, which requires a $100,000 payment per petition (with limited exceptions) and is supported by a DHS weighted selection process that prioritizes higher-skilled, higher-paid workers. The action continues to target IT staffing and outsourcing firms that have abused the program, and it maintains the requirement for ongoing rulemakings by DHS and DOL to further reform wage protections and program integrity.
RESTORING AMERICAN SALTWATER ANGLING AND RECREATION
This executive order directs federal agencies (primarily NOAA and the Department of Commerce) to shift fisheries management toward prioritizing recreational fishing over commercial interests by modernizing data collection, replacing outdated mail-in surveys with real-time mobile reporting, and allowing state-collected data to substitute for federal data when error rates are lower. It also mandates reviewing and potentially revising National Standards under the Magnuson-Stevens Act, rescinding regulations that restrict marine access, and launching pilot programs for iconic fisheries like Atlantic striped bass, with the goal of boosting the $1.2 trillion outdoor recreation sector.
Contract Details
Recipient
LEIDOS BIOMEDICAL RESEARCH INC
Award Amount
$342,250,840
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DELIVERY ORDER
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →